» Articles » PMID: 30871132

Thinking Outside the Bug: Molecular Targets and Strategies to Overcome Antibiotic Resistance

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2019 Mar 16
PMID 30871132
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Since their discovery in the early 20th century, antibiotics have been used as the primary weapon against bacterial infections. Due to their prophylactic effect, they are also used as part of the cocktail of drugs given to treat complex diseases such as cancer or during surgery, in order to prevent infection. This has resulted in a decrease of mortality from infectious diseases and an increase in life expectancy in the last 100 years. However, as a consequence of administering antibiotics broadly to the population and sometimes misusing them, antibiotic-resistant bacteria have appeared. The emergence of resistant strains is a global health threat to humanity. Highly-resistant bacteria like (methicillin-resistant) or (vancomycin-resistant) have led to complications in intensive care units, increasing medical costs and putting patient lives at risk. The appearance of these resistant strains together with the difficulty in finding new antimicrobials has alarmed the scientific community. Most of the strategies currently employed to develop new antibiotics point towards novel approaches for drug design based on prodrugs or rational design of new molecules. However, targeting crucial bacterial processes by these means will keep creating evolutionary pressure towards drug resistance. In this review, we discuss antibiotic resistance and new options for antibiotic discovery, focusing in particular on new alternatives aiming to disarm the bacteria or empower the host to avoid disease onset.

Citing Articles

Transient comparison of techniques to counter multi-drug resistant bacteria: prime modules in curation of bacterial infections.

Naveed M, Waseem M, Mahkdoom I, Ali N, Asif F, Hassan J Front Antibiot. 2025; 2():1309107.

PMID: 39816650 PMC: 11732137. DOI: 10.3389/frabi.2023.1309107.


High-Throughput Shotgun Metagenomics of Microbial Footprints Uncovers a Cocktail of Noxious Antibiotic Resistance Genes in the Winam Gulf of Lake Victoria, Kenya.

Khatiebi S, Kiprotich K, Onyando Z, Mwaura J, Wekesa C, Chi C J Trop Med. 2025; 2024:7857069.

PMID: 39741524 PMC: 11685326. DOI: 10.1155/jotm/7857069.


Antimicrobial activity of iron-depriving pyoverdines against human opportunistic pathogens.

Vollenweider V, Rehm K, Chepkirui C, Perez-Berlanga M, Polymenidou M, Piel J Elife. 2024; 13.

PMID: 39693130 PMC: 11655065. DOI: 10.7554/eLife.92493.


Pyoverdine-antibiotic combination treatment: its efficacy and effects on resistance evolution in .

Vollenweider V, Roncoroni F, Kummerli R Microlife. 2024; 5:uqae021.

PMID: 39502382 PMC: 11536758. DOI: 10.1093/femsml/uqae021.


Fungal L-Methionine Biosynthesis Pathway Enzymes and Their Applications in Various Scientific and Commercial Fields.

Rzad K, Kuplinska A, Gabriel I Biomolecules. 2024; 14(10).

PMID: 39456248 PMC: 11506715. DOI: 10.3390/biom14101315.


References
1.
Lai Y, Gallo R . AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009; 30(3):131-41. PMC: 2765035. DOI: 10.1016/j.it.2008.12.003. View

2.
Baroni A, Donnarumma G, Paoletti I, Longanesi-Cattani I, Bifulco K, Tufano M . Antimicrobial human beta-defensin-2 stimulates migration, proliferation and tube formation of human umbilical vein endothelial cells. Peptides. 2008; 30(2):267-72. DOI: 10.1016/j.peptides.2008.11.001. View

3.
Ruiz J . Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother. 2003; 51(5):1109-17. DOI: 10.1093/jac/dkg222. View

4.
MARGALITH P, PAGANI H . Rifomycin. XIV. Production of rifomycin B. Appl Microbiol. 1961; 9:325-34. PMC: 1057734. DOI: 10.1128/am.9.4.325-334.1961. View

5.
Paladino J, Rainstein M, Serrianne D, Przylucki J, Welage L, COLLURA M . Ampicillin-sulbactam versus cefoxitin for prophylaxis in high-risk patients undergoing abdominal surgery. Pharmacotherapy. 1994; 14(6):734-9. View